SG11201809243YA - Condensed heterocyclic compound - Google Patents

Condensed heterocyclic compound

Info

Publication number
SG11201809243YA
SG11201809243YA SG11201809243YA SG11201809243YA SG11201809243YA SG 11201809243Y A SG11201809243Y A SG 11201809243YA SG 11201809243Y A SG11201809243Y A SG 11201809243YA SG 11201809243Y A SG11201809243Y A SG 11201809243YA SG 11201809243Y A SG11201809243Y A SG 11201809243YA
Authority
SG
Singapore
Prior art keywords
heterocyclic compound
condensed heterocyclic
conden
sed
symbol
Prior art date
Application number
SG11201809243YA
Inventor
Youichi Kawakita
Takuto Kojima
Noriyuki Nii
Yoshiteru Ito
Nobuki Sakauchi
Hiroshi Banno
Xin Liu
Koji Ono
Keisuke Imamura
Shinichi Imamura
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of SG11201809243YA publication Critical patent/SG11201809243YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

CONDEN SED HETEROCYCLIC COMPOUND Provided is a compound represented by the following formula, or a salt thereof: [Chemical Form ula] [ wherein each symbol is as defined herein. ]. 5
SG11201809243YA 2016-04-28 2017-04-27 Condensed heterocyclic compound SG11201809243YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016091717 2016-04-28
PCT/JP2017/016717 WO2017188374A1 (en) 2016-04-28 2017-04-27 Condensed heterocyclic compound

Publications (1)

Publication Number Publication Date
SG11201809243YA true SG11201809243YA (en) 2018-11-29

Family

ID=60159711

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201809243YA SG11201809243YA (en) 2016-04-28 2017-04-27 Condensed heterocyclic compound
SG10201912270PA SG10201912270PA (en) 2016-04-28 2017-04-27 Condensed heterocyclic compound

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912270PA SG10201912270PA (en) 2016-04-28 2017-04-27 Condensed heterocyclic compound

Country Status (19)

Country Link
US (3) US10577382B2 (en)
EP (1) EP3450436B1 (en)
JP (2) JP6924182B2 (en)
KR (1) KR102431405B1 (en)
CN (1) CN109415384B (en)
BR (1) BR112018072039B1 (en)
CA (1) CA3021185A1 (en)
DK (1) DK3450436T3 (en)
EA (1) EA039529B1 (en)
ES (1) ES2927529T3 (en)
HR (1) HRP20221277T1 (en)
HU (1) HUE059954T2 (en)
LT (1) LT3450436T (en)
MA (1) MA44781B1 (en)
PL (1) PL3450436T3 (en)
PT (1) PT3450436T (en)
RS (1) RS63656B1 (en)
SG (2) SG11201809243YA (en)
WO (1) WO2017188374A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3450436T3 (en) 2016-04-28 2022-09-12 Takeda Pharmaceuticals Co CONDENSED HETEROCYCLIC COMPOUND
CN113773247A (en) * 2021-07-23 2021-12-10 无锡海伦生物科技有限公司 Preparation method of 2-amino-5-iodopyridine
WO2023190967A1 (en) * 2022-03-31 2023-10-05 Chordia Therapeutics株式会社 Biomarker for treatment of solid cancer by imidazo[4,5-b]pyridine derivative
CN115006411A (en) * 2022-07-26 2022-09-06 中南大学湘雅医院 Application of eudragit compounds, medicine and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
DE60026297T2 (en) 1999-05-21 2006-11-02 Bristol-Myers Squibb Co. PYRROLOTRIAZINE KINASEHEMMER
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP2308877B1 (en) * 2008-08-05 2014-01-22 Daiichi Sankyo Company, Limited Imidazopyridin-2-one derivatives
EP2987487B1 (en) * 2009-08-10 2020-10-07 Samumed, LLC Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
EP2464231A4 (en) * 2009-08-10 2013-02-06 Samumed Llc Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
WO2012003576A1 (en) * 2010-07-06 2012-01-12 Université de Montréal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
DK3450436T3 (en) * 2016-04-28 2022-09-12 Takeda Pharmaceuticals Co CONDENSED HETEROCYCLIC COMPOUND

Also Published As

Publication number Publication date
MA44781A (en) 2019-03-06
US20200140462A1 (en) 2020-05-07
US20190106437A1 (en) 2019-04-11
EA201892449A1 (en) 2019-05-31
JP6924182B2 (en) 2021-08-25
US11390634B2 (en) 2022-07-19
KR20190002547A (en) 2019-01-08
BR112018072039B1 (en) 2023-12-26
EP3450436A1 (en) 2019-03-06
PL3450436T3 (en) 2022-12-27
EA039529B1 (en) 2022-02-07
JP7130098B2 (en) 2022-09-02
HUE059954T2 (en) 2023-01-28
RS63656B1 (en) 2022-11-30
EP3450436A4 (en) 2019-10-30
US10981934B2 (en) 2021-04-20
EP3450436B1 (en) 2022-07-27
PT3450436T (en) 2022-09-29
KR102431405B1 (en) 2022-08-10
CN109415384A (en) 2019-03-01
BR112018072039A2 (en) 2019-02-12
CA3021185A1 (en) 2017-11-02
DK3450436T3 (en) 2022-09-12
SG10201912270PA (en) 2020-02-27
JP2021176901A (en) 2021-11-11
JPWO2017188374A1 (en) 2019-02-28
ES2927529T3 (en) 2022-11-08
WO2017188374A1 (en) 2017-11-02
US10577382B2 (en) 2020-03-03
MA44781B1 (en) 2022-10-31
LT3450436T (en) 2022-09-12
US20210115067A1 (en) 2021-04-22
CN109415384B (en) 2022-01-11
HRP20221277T1 (en) 2022-12-23

Similar Documents

Publication Publication Date Title
PH12020500150A1 (en) Herbicidal compounds
MX2018006474A (en) Microbiocidal oxadiazole derivatives.
MX2018004038A (en) Microbiocidal oxadiazole derivatives.
MX2018003845A (en) Microbiocidal oxadiazole derivatives.
MX2018008412A (en) Microbiocidal oxadiazole derivatives.
MX2019003807A (en) Microbiocidal oxadiazole derivatives.
MX2018015854A (en) Microbiocidal oxadiazole derivatives.
MY171055A (en) 3,5-disubstituted alkynylbenzene compound and salt thereof
PH12015502546B1 (en) 3-(4-isobutyl-2-methylphenyl) propanal as perfume ingredient
TN2011000286A1 (en) Spiroheterocyclic n-oxypiperidines as pesticides
MX2018007418A (en) Benzamide compounds and their use as herbicides.
SG11201809243YA (en) Condensed heterocyclic compound
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
IN2014MN02343A (en)
WO2016069321A3 (en) Electroactive materials
AU2012310674B2 (en) Radioactive fluorine labeled compound
WO2016064671A3 (en) Blue luminescent compounds
EA201991241A1 (en) METHOD FOR PRODUCING METHOXYMETHYLPYRIDINE DICARBOXYLATE
CL2018002094A1 (en) A process for preparing pyrrolo compound [3,2-d] pyrimidine and its intermediate
WO2018151479A3 (en) Heterocyclic compound and organic light emitting element comprising same
PH12020500341A1 (en) Pentacyclic compound
NZ627473A (en) Aryloxyacetamide compound and pesticide
EA201890476A1 (en) SUBSTITUTED 1,2-DIHYDRO-3H-PIRROLO [1,2-c] IMIDAZOL-3-ON AS ANTIBACTERIAL MEANS
WO2015163582A3 (en) Polyester-based plasticizer for resin
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds